Skip to main content

Table 1 Baseline patient and caregiver characteristics

From: Representativeness of European clinical trial populations in mild Alzheimer’s disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study

Characteristic

EXPEDITION RCTs (EU population)

GERAS observational study

p value for unadjusted baseline comparison

Patients, N

168

566

 

 Age (years)

71.9 (7.4)

77.3 (6.9)

< 0.001

 Sex (female), n (%)

85 (50.6)

271 (47.9)

0.83

 Patient education (years)

11.6 (3.9)

11.1 (3.3)

0.06

 Time since AD diagnosis (years)

1.7 (1.5)

1.7 (2.0)

0.90

 AD treatment category, n (%)

  

< 0.001

  AChEI only

129 (76.8)

411 (72.6)

 

  Memantine only

12 (7.1)

41 (7.2)

 

  AChEI + memantine

19 (11.3)

26 (4.6)

 

  No AD treatment

8 (4.8)

88 (15.5)

 

 MMSE score

23.1 (2.0)

23.3 (1.6)

0.15

Caregivers, N

168

566

 

 Age (years)

64.2 (12.2)

68.1 (11.6)

< 0.001

 Sex (female), n (%)

101 (60.5)

387 (68.5)

0.21

 Caregiver is patient’s spouse, n (%)

116 (69.5)

399 (70.6)

0.82

 Caregiver is working for pay, n (%)

57 (34.1)

133 (23.5)

0.04

  1. Data presented as mean (standard deviation) unless otherwise indicated. Percentages based on the number of patients/caregivers with available data (missing data ranged from zero to one participant in the EXPEDITION trials and from zero to three participants in the GERAS study). p-values in bold represent a significant difference between EXPEDITION and GERAS
  2. AChEI acetylcholinesterase inhibitor, AD Alzheimer’s disease, EU European, MMSE Mini-Mental State Examination, RCT randomised controlled trial